The Index sAGP is Valuable for Distinguishing Atypical Hepatocellular Carcinoma from Atypical Benign Focal Hepatic Lesions
Qing-Qing Luo,Qiao-Nan Li,Dan Cai,Song Jiang,Shao-Song Liu,Mao-Sheng Liu,Cong Lv,Jin-Ke Wang,Kun-He Zhang,Ting Wang
DOI: https://doi.org/10.2147/jhc.s443273
2024-02-09
Journal of Hepatocellular Carcinoma
Abstract:Qing-Qing Luo, &ast Qiao-Nan Li, &ast Dan Cai, Song Jiang, Shao-Song Liu, Mao-Sheng Liu, Cong Lv, Jin-Ke Wang, Kun-He Zhang, Ting Wang Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Jiangxi Institute of Gastroenterology & Hepatology, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ting Wang; Kun-He Zhang, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Jiangxi Institute of Gastroenterology & Hepatology, No. 17, Yongwai Zheng Street, Nanchang, Jiangxi, 330006, People's Republic of China, Tel +86-13361659001 ; +86-13007202818, Email ; Purpose: The differential diagnosis of atypical hepatocellular carcinoma (aHCC) and atypical benign focal hepatic lesions (aBFHL) usually depends on pathology. This study aimed to develop non-invasive approaches based on conventional blood indicators for the differential diagnosis of aHCC and aBFHL. Patients and Methods: Hospitalized patients with pathologically confirmed focal hepatic lesions and their clinical data were retrospectively collected, in which patients with HCC with serum alpha-fetoprotein (AFP) levels of ≤ 200 ng/mL and atypical imaging features were designated as the aHCC group (n = 224), and patients with benign focal hepatic lesions without typical imaging features were designated as the aBFHL group (n = 178). The performance of indexes (both previously reported and newly constructed) derived from conventional blood indicators by four mathematical operations in distinguishing aHCC and aBFHL was evaluated using the receiver operating characteristic (ROC) curve and diagnostic validity metrics. Results: Among ten previously reported derived indexes related to HCC, the index GPR, the ratio of γ-glutamyltransferase (GGT) to platelet (PLT), showed the best performance in distinguishing aHCC from aBFHL with the area under ROC curve (AUROC) of 0.853 (95% CI 0.814– 0.892), but the other indexes were of little value (AUROCs from 0.531 to 0.700). A new derived index, sAGP [(standardized AFP + standardized GGT)/standardized PLT], was developed and exhibited AUROCs of 0.905, 0.894, 0.891, 0.925, and 0.862 in differentiating overall, BCLC stage 0/A, TNM stage I, small, and AFP-negative aHCC from aBFHL, respectively. Conclusion: The sAGP index is an efficient, simple, and practical metric for the non-invasive differentiation of aHCC from aBFHL. Keywords: atypical hepatocellular carcinoma, differential diagnosis, conventional blood indicator, derived index, sAGP Primary hepatic carcinoma (PHC) is one of the common malignancies, with an estimated 906,000 new cases and 830,000 deaths in 2020, ranking as the sixth most frequent cancer and the third leading cause of cancer-related death worldwide. 1 Due to difficulties in early diagnosis, 60% of patients with PHC have progressed to intermediate or advanced stages at the time of diagnosis, and the majority lose the opportunity for radical surgery, resulting in an overall 5-year survival rate of <10%. 2 In contrast, early diagnosis followed by effective treatment can significantly change the course of the disease and improve prognosis, resulting in an overall 5-year survival rate of >70%. 3 Therefore, early diagnosis of PHC is important. Hepatocellular carcinoma (HCC) accounts for 90% of PHC. At present, the clinical diagnosis of HCC mainly depends on serum alpha-fetoprotein (AFP) and imaging examination. In the Asia-Pacific guidelines for the management of hepatocellular carcinoma, AFP ≥ 200 ng/mL is used as a criterion for HCC surveillance. 4 However, up to 30% of HCC patients do not present with elevated serum AFP levels. 5 In addition, approximately 40% of patients with hepatitis and 30% of patients with cirrhosis have elevated AFP levels, even exceeding 200ng/mL. 6 Imaging examination is an important tool in the diagnosis of HCC. The typical imaging features of HCC are hyper-enhancement during the arterial phase followed by washout during the portal and late phases. However, 5–41% of HCC do not have these typical features, while some benign focal hepatic lesions (BFHL) are radiologically difficult to distinguish from atypical HCC, which leads to the requirement for pathological examination to clarify the diagnosis. 7 Unfortunately, preoperative pathological examination requires liver biopsy to obtain tissue specimens. Liver biopsy, in addition to causing pain to the patient, may cause bleeding, infection, needle track tumor seeding, and injury (pneumothorax, hemothorax, and injury to the gallbladder, bowel, or kidney). Therefore, non-invasive diagnostic approaches are important for patien -Abstract Truncated-
oncology